Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861572 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL2705958 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL10491008 | 0.93 | ALDH1A1 (0.62) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL22868105 | 0.85 | CA12 (0.46) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL4124134 | 0.85 | TSHR (0.47) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL4124137 | 0.85 | TSHR (0.47) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL2386329 | 0.83 | TSHR (0.46) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL6257260 | 0.83 | HIF1A (0.44) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL22950649 | 0.83 | TSHR (0.46) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 | |
| SCHEMBL5860329 | 0.83 | MEN1 (0.47) | ALDH1A1TSHRHSD17B10CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2492275-B1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING A TRIDENTATE LIGAND AND MANUFACTURING METHOD AND USAGE THEREFOR | TAKASAGO PERFUMERY CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| EP-1970360-B1 | Method for producing alcohols | TAKASAGO PERFUMERY CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-2492275-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING A TRIDENTATE LIGAND AND MANUFACTURING METHOD AND USAGE THEREFOR | Takasago International Corporation (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-7569735-B2 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | TAKASAGO INTERNATIONAL CORPORATION | 2008-09-18 | — | — | US | disclosed |
| EP-1970360-A1 | Method for producing alcohols | Takasago International Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-7232923-B2 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL INNOVATIONS LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232923-B2 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL INNOVATIONS LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7145030-B2 | Production method for optically active N-aryl-β-amino acid compounds | AJINOMOTO CO., INC. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040267043-A1 | Production method for optically active N-aryl-beta-amino acid compounds | AJINOMOTO CO., INC. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1471050-A1 | Production method for optically active N-aryl-beta-amino acid compounds | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 1599/4885TSHR 738/4885HSD17B10 901/4885 |
| US-20080228012-A1 | Reducing esters or lactones with hydrogen gas in presence of ruthenium catalyst; high yield and high catalytic efficiency under an industrially advantageous condition of relatively low hydrogen pressure and low reaction temperature | LPXN, LIPE, MLX | ALDH1A1 1512/4885TSHR 1192/4885HSD17B10 981/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 1599/4885TSHR 738/4885HSD17B10 901/4885 |
| US-20040267043-A1 | Production method for optically active N-aryl-beta-amino acid compounds | AADAT, AADAC, DDC | ALDH1A1 588/4885TSHR 3165/4885HSD17B10 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.